Journey Strategic Wealth LLC Buys 1,678 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA)

Journey Strategic Wealth LLC boosted its stake in ADMA Biologics, Inc. (NASDAQ:ADMA) by 11.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 16,718 shares of the biotechnology company’s stock after purchasing an additional 1,678 shares during the period. Journey Strategic Wealth LLC’s holdings in ADMA Biologics were worth $287,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. State Street Corp boosted its position in shares of ADMA Biologics by 61.4% in the third quarter. State Street Corp now owns 13,004,993 shares of the biotechnology company’s stock worth $259,970,000 after purchasing an additional 4,945,063 shares during the period. Geode Capital Management LLC boosted its holdings in ADMA Biologics by 2.6% in the 3rd quarter. Geode Capital Management LLC now owns 5,381,985 shares of the biotechnology company’s stock worth $107,606,000 after buying an additional 137,989 shares during the period. Perpetual Ltd bought a new position in shares of ADMA Biologics in the fourth quarter worth about $62,300,000. Assenagon Asset Management S.A. boosted its stake in shares of ADMA Biologics by 2.7% in the third quarter. Assenagon Asset Management S.A. now owns 3,474,455 shares of the biotechnology company’s stock worth $69,454,000 after acquiring an additional 92,281 shares during the period. Finally, Lord Abbett & CO. LLC bought a new position in shares of ADMA Biologics in the third quarter worth about $61,858,000. Institutional investors own 75.68% of the company’s stock.

ADMA Biologics Price Performance

ADMA stock opened at $16.47 on Tuesday. The company has a quick ratio of 3.26, a current ratio of 7.09 and a debt-to-equity ratio of 0.48. ADMA Biologics, Inc. has a 52 week low of $5.02 and a 52 week high of $23.64. The company has a fifty day simple moving average of $18.10 and a two-hundred day simple moving average of $17.61. The firm has a market capitalization of $3.89 billion, a P/E ratio of 58.82 and a beta of 0.75.

ADMA Biologics (NASDAQ:ADMA) last announced its quarterly earnings results on Thursday, November 7th. The biotechnology company reported $0.15 EPS for the quarter, beating analysts’ consensus estimates of $0.13 by $0.02. The firm had revenue of $119.84 million during the quarter, compared to the consensus estimate of $107.25 million. ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. During the same quarter last year, the firm earned $0.01 EPS. Analysts anticipate that ADMA Biologics, Inc. will post 0.51 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on ADMA shares. HC Wainwright boosted their target price on shares of ADMA Biologics from $18.00 to $26.00 and gave the stock a “buy” rating in a report on Friday, November 8th. Raymond James boosted their price target on shares of ADMA Biologics from $18.00 to $25.00 and gave the stock a “strong-buy” rating in a research note on Friday, November 8th.

Insider Buying and Selling

In other news, CFO Brad L. Tade sold 15,000 shares of the firm’s stock in a transaction dated Friday, November 22nd. The shares were sold at an average price of $21.15, for a total value of $317,250.00. Following the completion of the sale, the chief financial officer now owns 199,433 shares in the company, valued at approximately $4,218,007.95. This trade represents a 7.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 3.70% of the stock is owned by corporate insiders.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.